secwatch.observer — SEC 8-K summary
======================================

Issuer:     CYTOKINETICS INC (CYTK)
CIK:        0001061983
Form:       8-K
Filed at:   2026-02-17T23:59:59+00:00
Accession:  0001193125-26-053049
Event type: regulatory
Sentiment:  positive
Materiality: 0.90
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Cytokinetics announces European Commission approval of MYQORZO (aficamten) for obstructive HCM
--------------------------------------------------------------------------------

- European Commission approved MYQORZO (aficamten) for symptomatic obstructive HCM in adults.
- Approved dosage strengths: 5 mg, 10 mg, 15 mg, and 20 mg tablets.
- MYQORZO is an allosteric, reversible inhibitor of cardiac myosin motor activity.
- Indication covers NYHA class II-III obstructive hypertrophic cardiomyopathy.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1061983/000119312526053049/0001193125-26-053049-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1061983/000119312526053049/cytk-20260217.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-053049

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer